$2.38
0.00% yesterday
Nasdaq, May 16, 10:00 pm CET
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Aquestive Therapeutics, Inc. Stock price

$2.38
-0.12 4.80% 1M
-2.26 48.71% 6M
-1.18 33.15% YTD
-0.90 27.44% 1Y
+1.13 90.40% 3Y
-4.06 63.04% 5Y
-13.67 85.17% 10Y
Nasdaq, Closing price Fri, May 16 2025
+0.00 0.00%
ISIN
US03843E1047
Symbol
AQST
Sector
Industry

Key metrics

Market capitalization $236.40m
Enterprise Value $292.30m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.39
P/S ratio (TTM) P/S ratio 4.36
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 5.29%
Revenue (TTM) Revenue $54.23m
EBIT (operating result TTM) EBIT $-41.18m
Free Cash Flow (TTM) Free Cash Flow $-49.04m
Cash position $68.66m
EPS (TTM) EPS $-0.58
P/E forward negative
P/S forward 5.20
EV/Sales forward 6.43
Short interest 11.22%
Show more

Is Aquestive Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,790 stocks worldwide.

Aquestive Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

9x Buy
100%

Analyst Opinions

9 Analysts have issued a Aquestive Therapeutics, Inc. forecast:

Buy
100%

Financial data from Aquestive Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
54 54
5% 5%
100%
- Direct Costs 17 17
16% 16%
32%
37 37
20% 20%
68%
- Selling and Administrative Expenses 58 58
72% 72%
107%
- Research and Development Expense 20 20
27% 27%
36%
-41 -41
122% 122%
-75%
- Depreciation and Amortization 0.65 0.65
47% 47%
1%
EBIT (Operating Income) EBIT -41 -41
112% 112%
-76%
Net Profit -54 -54
89% 89%
-100%

In millions USD.

Don't miss a Thing! We will send you all news about Aquestive Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Aquestive Therapeutics, Inc. Stock News

Neutral
Seeking Alpha
4 days ago
Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2025 Earnings Conference Call May 13, 2025 8:00 AM ET Company Participants Brian Korb - IR Dan Barber - CEO Ernie Toth - CFO Sherry Korczynski - SVP of Sales and Marketing Carl Kraus - CMO Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Stanley Kristen Kluska - Cantor Fitzgerald Jason Butler - Citizens JMP Raghura...
Neutral
GlobeNewsWire
5 days ago
WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced financial results for the first quarter ended March 31, 2025, and provided a strategic business update.
Positive
Seeking Alpha
13 days ago
AQST's Anaphylm, a sublingual epinephrine film, shows strong potential with FDA approval expected in Q2'25 and a $1B annual revenue target. AQST's financial health is weaker compared to competitors, with a probable need to raise $100M-$150M in the next 2-3 years. My base-case DCF model estimates a fair value of $8.11, offering a 179% upside, with an optimistic scenario reaching $15.38.
More Aquestive Therapeutics, Inc. News

Company Profile

Aquestive Therapeutics, Inc. is a specialty pharmaceutical company focused on identifying, developing, and commercializing differentiated products to address unmet medical needs. The company has a late-stage proprietary product pipeline focused on the treatment of Central nervous system (CNS) diseases, as well as orally-administered complex molecules that can be alternatives to invasively-administered standard of care therapies. Its product candidates include Libervant, Sympazan, and AQST-117 (Riluzole). Aquestive Therapeutics develops and delivers drugs via its PharmFilm technology. The firm also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms. In addition to its proprietary product candidates, the company, with its partners, has a portfolio of development-stage products and commercialized products, such as Suboxone, a prescription medicine for the treatment of opioid dependence. The company was founded in January 2004 and is headquartered in Warren, NJ.

Head office United States
CEO Daniel Barber
Employees 142
Founded 2004
Website www.aquestive.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today